Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Increlex® on Children With Crohn Disease
NCT00764699 · Nationwide Children's Hospital · PHASE2/PHASE3 · terminated · last registry update 2018-03-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left institution” | – | Registry record, Nationwide Children's Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IGF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-10-09Results posted on the registry: Merck Sharp & Dohme LLC, dalotuzumab (NCT00635778)
- 2018-09-13Also stopped (terminated): Novartis Pharmaceuticals, BYL719 + AMG 479 (NCT01708161)
- 2018-09-13Results posted on the registry: University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-09-13Also stopped (terminated): University Health Network, Toronto, ASP7487, Velcade, Dexamethasone (NCT01672736)
- 2018-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, Temozolomide + Vincristine (NCT00960063)
- 2018-08-24Also stopped (terminated): Merck Sharp & Dohme LLC, Carboplatin + Epirubicin (NCT00954512)
- 2018-08-23Also stopped (terminated): Merck Sharp & Dohme LLC, robatumumab (NCT00617890)
- 2018-08-16Also stopped (terminated): Merck Sharp & Dohme LLC, dalotuzumab + MK-0752 (NCT01243762)
- 2018-06-28Results posted on the registry: Novartis Pharmaceuticals, BYL719 + AMG 479 (NCT01708161)
- 2018-03-26Results posted on the registry: Boston Children's Hospital, Recombinant Human Insulin Growth Factor 1 (rhIGF-1) + Placebo (NCT01777542)
- 2018-03-09Phase 3 first posted: Amgen, Teprotumumab (NCT03461211)
- 2017-12-27Results posted on the registry: Dana-Farber Cancer Institute, AMG 479 (NCT01024387)
- 2017-11-21Also stopped (terminated): Emory University, Sorafenib and OSI-906 (NCT01334710)
- 2017-10-30Results posted on the registry: Merck Sharp & Dohme LLC, dalotuzumab + MK-0752 (NCT01243762)
- 2017-10-02Phase 3 first posted: Amgen, Teprotumumab (NCT03298867)
- 2017-09-05Also stopped (terminated): Merrimack Pharmaceuticals, MM-151 + MM-121 (NCT02538627)
- 2017-08-30Results posted on the registry: Amgen, teprotumumab + normal saline (NCT01868997)
- 2017-08-02Results posted on the registry: Merck Sharp & Dohme LLC, Dalotuzumab 10 mg/kg + Cetuximab (NCT00925015)
- 2017-06-22Results posted on the registry: Boston Children's Hospital, rhIGF-1 (NCT01253317)
- 2017-06-15Results posted on the registry: Merck Sharp & Dohme LLC, Dalotuzumab (NCT00694356)
- 2017-06-07Results posted on the registry: Shire, rhIGF-I/rhIGFBP-3 (NCT01096784)
- 2017-04-14Results posted on the registry: Merck Sharp & Dohme LLC, dalotuzumab (MK0646) (NCT00759785)
- 2017-03-21Results posted on the registry: Merck Sharp & Dohme LLC, Dalotuzumab (NCT00701103)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision